

AN 1997-372474 [34] WPIDS

CR 1996-362631 [36]

DNC C1997-119959

TI New thiol derivatives useful in treating cardiovascular disorders - are inhibitors of angiotensin converting enzyme and neutral endo-peptidase..

DC B03 B05

IN FANTUCCI, M; NORCINI, G; PELLACINI, F; ROMAGNANO, S; SANTANGELO, F; SEMERARO, C; ROMAGMANO, S; SANTORLO, F

PA (ZAMB) ZAMBON GROUP SPA

CYC 73

PI WO 9724342 A1 19970710 (199734)* EN 35p

RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD
SE SZ UG

W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL
IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

ZA 9610891 A 19970923 (199744) 32p

AU 9713018 A 19970728 (199746)

NO 9802977 A 19980827 (199844)

IT 1277737 B 19971112 (199845)

EP 877740 A1 19981118 (199850) EN

R: AL AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV MC NL PT SE SI

CZ 9802046 A3 19981111 (199851)

SK 9800889 A3 19981202 (199907)

CN 1206411 A 19990127 (199923)

BR 9612373 A 19990713 (199939)

NZ 325785 A 19990929 (199945)

AU 713156 B 19991125 (200006)

HU 9903636 A2 20000228 (200020)

JP 2000502687 W 20000307 (200023) 41p

KR 99076809 A 19991015 (200051)

MX 9805250 A1 19990201 (200055)

NO 310914 B1 20010917 (200158)

IL 124915 A 20011031 (200174)

SK 282977 B6 20030109 (200309)

ADT WO 9724342 A1 WO 1996-EP5663 19961217; ZA 9610891 A ZA 1996-10891
19961223; AU 9713018 A AU 1997-13018 19961217; NO 9802977 A WO 1996-EP5663
19961217, NO 1998-2977 19980626; IT 1277737 B IT 1995-MI2773 19951228; EP
877740 A1 EP 1996-944583 19961217, WO 1996-EP5663 19961217; CZ 9802046 A3
WO 1996-EP5663 19961217, CZ 1998-2046 19961217; SK 9800889 A3 WO
1996-EP5663 19961217, SK 1998-889 19961217; CN 1206411 A CN 1996-199354
19961217; BR 9612373 A BR 1996-12373 19961217, WO 1996-EP5663 19961217; NZ
325785 A NZ 1996-325785 19961217, WO 1996-EP5663 19961217; AU 713156 B AU
1997-13018 19961217; HU 9903636 A2 WO 1996-EP5663 19961217, HU 1999-3636
19961217; JP 2000502687 W WO 1996-EP5663 19961217, JP 1997-524001

19961217; KR 99076809 A WO 1996-EP5663 19961217, KR 1998-704934 19980626;
MX 9805250 A1 MX 1998-5250 19980626; NO 310914 B1 WO 1996-EP5663 19961217,
NO 1998-2977 19980626; IL 124915 A IL 1996-124915 19961217; SK 282977 B6
WO 1996-EP5663 19961217, SK 1998-889 19961217

FDT AU 9713018 A Based on WO 9724342; EP 877740 A1 Based on WO 9724342; CZ
9802046 A3 Based on WO 9724342; BR 9612373 A Based on WO 9724342; NZ
325785 A Based on WO 9724342; AU 713156 B Previous Publ. AU 9713018, Based
on WO 9724342; HU 9903636 A2 Based on WO 9724342; JP 2000502687 W Based on
WO 9724342; KR 99076809 A Based on WO 9724342; NO 310914 B1 Previous Publ.
NO 9802977; IL 124915 A Based on WO 9724342; SK 282977 B6 Previous Publ.
SK 9800889, Based on WO 9724342

PRAI IT 1995-MI2773 19951228

AN 1997-372474 [34] WPIDS

CR 1996-362631 [36]

AB WO 9724342 A UPAB: 20030206

Thiol derivatives of formula $\text{RCH}_2\text{CHR}_1\text{CONHCH}(\text{CH}_2\text{R}_3)\text{COOR}_2$ (I) and their salts are new: R = mercapto or R_4COS convertible in an organism to a mercapto group; R1 = 2-4C alkyl, Ar or $\text{Ar}(1-6\text{C})\text{alkyl}$; Ar = phenyl or Het (both optionally substituted by one or more halo, OH, TO, T, TS, TSO_2 , TOCO , 1-3C alkyl (containing one or more F atoms), carboxy, nitro, NH_2 , NH_2CO , acylamino, NH_2SO_2 , TNH, (T)2N, TNHCO or (T)2NCO); Het = a 5-6 membered aromatic heterocycle containing 1-2 N, O or S atoms; R2 = H, 1-4C alkyl or benzyl; R3 = phenyl substituted by Het (optionally substituted as for Ar); R4 = 1-4C alkyl or phenyl; T = 1-6C alkyl.

USE - (I) have dual angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitory activity. They are useful in treatment of cardiovascular disorders.

Dwg.0/0

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 277/30, A61K 31/425, C07D 213/55, 307/54, 239/26, 333/24, 241/12, 417/12		A1	(11) International Publication Number: WO 97/24342 (43) International Publication Date: 10 July 1997 (10.07.97)
<p>(21) International Application Number: PCT/EP96/05663</p> <p>(22) International Filing Date: 17 December 1996 (17.12.96)</p> <p>(30) Priority Data: MI95A002773. 28 December 1995 (28.12.95) IT</p> <p>(71) Applicant (for all designated States except US): ZAMBON GROUP S.P.A. [IT/IT]; Via della Chimica, 9, I-36100 Vicenza (IT).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): PELLACINI, Franco [IT/IT]; Via G. Balla, 14, I-20151 Milano (IT). FANTUCCI, Mario [IT/IT]; Via Valparaiso, 7/A, I-20144 Milano (IT). NORCINI, Gabriele [IT/IT]; Via A. Volta, 42, I-21010 Vizzola Ticino (IT). ROMAGNANO, Stefano [IT/IT]; Via D. Scarlatti, 33, I-20090 Buccinasco (IT). SANTANGELO, Francesco [IT/IT]; Via Passo di Fargorida, 5, I-20148 Milano (IT). SEMERARO, Claudio [IT/IT]; Via S. Allende, 4/6, I-20091 Bresso (IT).</p> <p>(74) Agent: LONGONI, Alessandra; Zambon Group S.p.A., Corp. Patent & Trademark Dept., Via Lillo del Duca, 10, I-20091 Bresso (Milan) (IT).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	

(54) Title: THIOL DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY

(57) Abstract

Compounds of formula (I), wherein R, R₁, R₂, and R₃ have the meanings reported in the description, processes for their preparation and pharmaceutical compositions which contain them as active ingredients are described. The compounds of formula (I) are endowed with a mixed ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

"Thiol derivatives with metallopeptidase inhibitory activity"

The present invention relates to thiol derivatives with metallopeptidase inhibitory activity and,
5 more particularly, it relates to N-mercaptoproacyl phenylalanine derivatives useful in the treatment of cardiovascular diseases.

The pharmacologic interest towards the study of metallopeptidase inhibitory molecules derives from the role that said enzymes exert on the level of the cardiocirculatory system.

It is well-known in fact that compounds with angiotensin converting enzyme (ACE) inhibitory activity are mainly useful in the treatment of hypertension, heart failure and post-infarct in that they inhibit the formation of angiotensin II, a substance which produces several effects among which the increase of the blood pressure.

Compounds with endothelin converting enzyme (ECE) inhibitory activity are useful as anti-vasoconstrictors because they inhibit the formation of endothelin, a 21 amino acid peptide with vasoconstrictor activity.

Instead, compounds with inhibitory activity of the neutral endopeptidase (NEP) enzyme, also called enkephalinase, are useful as vasodilators since the NEP enzyme is responsible for the inactivation, not only of endogenous enkephaline, but also of some natriuretic factors such as, for instance, the atrial factor (ANF), a hormone secreted by heart which increases the vaso-dilatation and, on the renal level, increases diuresis and natriuresis.

Therefore, even exerting their action on the cardiovascular system with different mechanisms of action, the compounds with metallopeptidase inhibitory activity are generally used, alone or in combination, in the treatment of hypertension, renal failure, congestive heart failure and ischemic cardiopathologies.

25 Among the thiol derivatives inhibitors of metallopeptidases, Thiorphan [(DL-(3-mercaptop-2-benzylpropanoyl)glycine], described for the first time by Roques et al. in Nature, Vol. 288, pages 286-288, (1980), and Captopril (The Merck Index, XI ed., No. 1773, page 267) are considered the parent compounds for NEP-inhibitors and ACE-inhibitors, respectively.

Other molecules having thiol structure endowed with metallopeptidase inhibitory activity are 30 described in the literature.

The US patents No. 4,401,677 and No. 4,199,512 (both in the name of E.R. Squibb & Sons,

- 2 -

Inc.) describe mercaptoalkanoyl amino acids endowed with enkephalinase inhibitory activity and ACE-inhibitory activity, respectively.

5 The European patent application No. 0419327 (Société Civile Bioproject) describes amino acid derivatives endowed with enkephalinase and ACE inhibitory activity, respectively.

The European patent application No. 0449523 (E.R. Squibb & Sons, Inc.) describes mercapto or acylthio trifluoromethylamides with NEP-inhibitory activity.

10 The international patent application No. WO 93/08162 [Rhone-Poulenc Rorer S.A. - Institut National de la Santé et de la Recherche Médicale (INSERM)] describes β,β -disubstituted α -mercaptopropylpropionylamides endowed with mixed ACE/NEP inhibitory activity.

The European patent application No. 0524553 [Institut National de la Santé et de la Recherche Médicale (INSERM)] describes acylmercaptoalkanoyldipeptides endowed with neutral endopeptidase and peptidyldipeptidase A inhibitory activity.

15 The European patent application No. 0566157 (Schering Corporation) describes thiol derivatives such as, for instance, N-mercaptoacyl amino acids, endowed with NEP-inhibitory activity.


α -Mercaptoacyl dipeptides endowed with ACE-inhibitory and NEP-inhibitory activity are also described by S.S. Bhagwat et al. in Bioorganic & Medicinal Chemistry Letters, 7, 735-738, 1995.

20 In this last work the authors conclude that, while the presence of a biphenylmethyl group confers an interesting mixed ACE/NEP-inhibitory activity at the molecules having an α -mercaptoprotoacyl dipeptide structure, the substitution of the biphenyl group with groups such as α - or β -naphthyl causes a significant loss of activity.

Now we have found N-mercaptoacyl phenylalanine derivatives which are endowed with a 25 remarkable inhibitory activity on the angiotensin converting enzyme as well as on the neutral endopeptidase enzyme (mixed or dual ACE/NEP inhibitory activity) which makes them particularly useful in the therapy of cardiovascular pathologies.

Therefore, object of the present invention are the compounds of formula

- 3 -



wherein

R is a mercapto group or a R_4COS group convertible in the organism to mercapto group;

R₁ is a straight or branched C₂-C₄ alkyl group or an aryl or arylalkyl group having from 1 to 6 carbon atoms in the alkyl moiety wherein the aryl is a phenyl or a 5 or 6 membered aromatic heterocycle with one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, optionally substituted with one or more substituents, the same or different, selected from the group consisting of halogen atoms, hydroxy groups, alkoxy, alkyl, alkylthio, alkylsulphonyl or alkoxy carbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety, C₁-C₃ alkyl groups containing one or more fluorine atoms, carboxy groups, nitro groups, amino or aminocarbonyl groups, acylamino groups, aminosulphonyl groups, mono- or di-alkylamino or mono- or di-alkylaminocarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety;

R₂ is a hydrogen atom, a straight or branched C₁-C₄ alkyl or a benzyl group;

R₃ is a phenyl group substituted with a 5 or 6 membered aromatic heterocycle with one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, being the phenyl and the heterocyclic groups optionally substituted with one or more substituents, the same or different, as indicated for R₁;

R₄ is a straight or branched C₁-C₄ alkyl group or a phenyl group;

25 the carbon atoms marked with an asterisk are stereogenic centers; and pharmaceutically acceptable salts thereof.

The compounds of formula I contain two stereogenic centers and can thus exist in the form of stereoisomers:

Therefore, object of the present invention are the compounds of formula I in the form of 30 stereoisomeric mixture as well as in the form of single stereoisomers.

The compounds of formula I object of the present invention are endowed with a mixed ACE/NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.

Although both terms mixed and dual are indifferently used, the term dual is the one more

- 4 -

commonly accepted in the literature for compounds endowed contemporaneously with ACE- and NEP-inhibitory activity.

In the present context, the terms mixed and dual are to be considered equivalent.

5 In the present description, unless otherwise specified, with the term straight or branched alkyl group we intend an alkyl such as methyl, ethyl, n.propyl, isopropyl, n.butyl, sec-butyl, tert-butyl, isobutyl, n.pentyl, 2-pentyl, 3-pentyl, isopentyl, tert-pentyl, n.hexyl and isohexyl group; with the term straight or branched alkoxy group we intend an alkoxy such as methoxy, ethoxy, n.propoxy and isopropoxy group; with the term halogen atom we intend a fluorine, chlorine, 10 bromine or iodine atom; with the term acyl we intend an acyl group deriving from an aliphatic or aromatic carboxylic acid such as acetic, propionic, butyric and benzoic acid; with the term 5 or 6 membered aromatic heterocycle containing 1 or 2 heteroatoms selected among nitrogen, oxygen and sulphur we intend a group such as thiazole, isoxazole, oxazole, isothiazole, pyrazole, imidazole, thiophene, pyrrole, pyridine, pyrimidine, pyrazine, pyridazine and furan, optionally benzocondensed.

Examples of pharmaceutically acceptable salts of the compounds of formula I are the salts with alkali or alkali-earth metals and the salts with pharmaceutically acceptable organic bases.

Preferred compounds of formula I are the compounds wherein R_3 is a phenyl group substituted in position 4 with a heterocyclic group.

20 More preferred compounds, in this class, are the compounds of formula I wherein R_1 represents an arylalkyl group optionally substituted with one or more substituents, the same or different, selected from the group consisting of halogen atoms, hydroxy, alkyl or alkoxy.

Still more preferred compounds, in this class, are the compound of formula I wherein R_1 represents a phenylalkyl group optionally substituted with one or more substituents, the same or

25 different, selected from the group consisting of halogen atoms, hydroxy, alkyl or alkoxy.

Preferred examples of pharmaceutically acceptable salts of the compounds of formula I are the salts with alkali metals such as sodium, lithium and potassium.

It is clear to the man skilled in the art that the compounds of formula I wherein R is a R_4COS

group convertible in the organism to mercapto group, as well as the compounds of formula I

30 wherein R_2 is an alkyl or benzyl group, are biologic precursors (pro-drugs) of the corresponding compounds of formula I wherein R is a mercapto group (R=SH) or R_2 is a hydrogen atom

- 5 -

(R₂=H), respectively.

Specific examples of preferred compounds of formula I, object of the present invention, are:

N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-thiazolyl)-phenylalanine methyl ester;

5 N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-pyridyl)-phenylalanine methyl ester;

N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(3-pyridyl)-phenylalanine benzyl ester;

N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-furyl)-phenylalanine methyl ester;

N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(5-pyrimidinyl)phenylalanine ethyl ester;

10 N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-pyrazinyl)-phenylalanine methyl ester;

N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-thienyl)-phenylalanine methyl ester;

N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(3-thienyl)-phenylalanine methyl ester;

15 N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(3-furyl)-phenylalanine methyl ester;

N-[3-phenylcarbonylthio-2-(3-pyridylmethyl)propionyl]-4-(2-thiazolyl)-phenylalanine methyl ester;

N-[3-acetylthio-2-(3-methoxyphenyl)methyl-propionyl]-4-(2-thiazolyl)-phenylalanine methyl ester;

20 N-[3-acetylthio-2-(2-fluorophenyl)methyl-propionyl]-4-(2-thiazolyl)-phenylalanine methyl ester;

N-[3-phenylcarbonylthio-2-(2-thienyl)methyl-propionyl]-4-(2-thiazolyl)-phenylalanine methyl ester;

N-[2-(2-furyl)methyl-3-phenylcarbonylthio-propionyl]-4-(2-thiazolyl)-phenylalanine methyl ester;

25 N-[2-(3-methyl-5-isoxazolyl)methyl-3-phenylcarbonylthio-propionyl]-4-(2-thiazolyl)-phenylalanine methyl ester;

N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-thiazolyl)-phenylalanine;

N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-pyridyl)-phenylalanine;


30 N-(3-mercaptop-2-phenylmethylpropionyl)-4-(3-pyridyl)-phenylalanine;

N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-furyl)-phenylalanine;

- 6 -

N-(3-mercaptop-2-phenylmethylpropionyl)-4-(5-pyrimidinyl)-phenylalanine;
 N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-pyrazinyl)-phenylalanine;
 N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-thienyl)-phenylalanine;
 5 N-(3-mercaptop-2-phenylmethylpropionyl)-4-(3-thienyl)-phenylalanine;
 N-(3-mercaptop-2-phenylmethylpropionyl)-4-(3-furyl)-phenylalanine;
 N-[3-mercaptop-2-(3-pyridylmethyl)propionyl]-4-(2-thiazolyl)-phenylalanine;
 N-[3-mercaptop-2-(3-methoxyphenyl)methyl-propionyl]-4-(2-thiazolyl)-phenylalanine;
 N-[3-mercaptop-2-(2-thienyl)methyl-propionyl]-4-(2-thiazolyl)-phenylalanine;
 10 N-[3-mercaptop-2-(3-methyl-5-isoxazolyl)methyl-propionyl]-4-(2-thiazolyl)-phenylalanine;
 N-[2-(2-fluorophenyl)methyl-3-mercaptop-propionyl]-4-(2-thiazolyl)-phenylalanine;
 N-[2-(2-furyl)methyl-3-mercaptop-propionyl]-4-(2-thiazolyl)-phenylalanine.


The preparation of the compounds of formula I, object of the present invention, is carried out according to a synthetic process comprising the reaction between a compound of formula



wherein

20 R and R₁ have the above reported meanings;

and a phenylalanine derivative of formula



wherein

R₂ and R₃ have the above reported meanings.

The condensation reaction is carried out according to conventional techniques of the chemistry of peptides.

30 Before carrying out the reaction it can be useful to properly protect the optional functional groups which could interfere in the reaction.

The optional protection is carried out according to conventional techniques.

In this respect the compounds wherein R is a R₄COS group are preferably used as intermediates of formula II, thus obtaining the corresponding compounds of formula I wherein

- 7 -

R=R₄COS from which, by hydrolysis, the compounds of formula I wherein R=SH can be obtained.

5 The evaluation of the usefulness of the optional protection as well as the selection of the kind of adopted protection, according to the reaction to be carried out and to the functional groups to be protected, are within the normal knowledge of the man skilled in the art.

The removal of the optional protective groups is carried out according to conventional techniques.

For a general reference to the use of protective groups in organic chemistry see Theodora W. 10 Greene and Peter G.M. Wuts "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., II Ed., 1991.

The compounds of formula II are known or easily prepared according to conventional methods as described, for instance, in British patent No. 1576161 in the name of E.R. Squibb & Sons Inc.

15 Alternatively, the compounds of formula II can be prepared according to the synthetic methods described by M.C. Fournié-Zalusky et al. in J. Med. Chem. 1994, 37, 1070-1083.

Also the intermediate compounds of formula III are known or easily prepared according to known methods.

For instance, the compounds of formula III can be prepared according to the synthetic methods described by W. C. Shieh et al. in J. Org. Chem. 1992, 57, 379-381.

Alternatively, the compounds of formula III can be prepared by coupling methods (cross-coupling) starting from halogenated heterocyclic compounds and stannyli phenylalanine derivatives, as described by D.S. Wilbur et al. in Bioconjugate Chem., 1993, 4, 574-580.

25 The compounds of formula I in the form of single stereoisomers are prepared by stereoselective synthesis or by separation of the stereoisomeric mixture according to conventional techniques.

Also the preparation of the salts of the compounds of formula I, object of the present invention, is carried out according to conventional techniques.

30 The compounds of formula I, object of the present invention, are endowed with a mixed ACE/NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.

The inhibitory activity of the compounds of formula I was evaluated by means of in vitro tests

- 8 -

(example 8).

In particular, the inhibitory activity of the compounds of formula I was evaluated in comparison to the aforementioned Thiorphan and Captopril.

5 The in vitro inhibitory activity of the compounds of formula I, expressed as IC₅₀ value, resulted at nM concentrations.

Said activity resulted to be comparable to that of Captopril, to what it concerns the ACE-inhibitory activity, and greater than that of Thiorphan, to what it concerns the NEP-inhibitory activity.

10 The inhibitory activity of the compounds of formula I, moreover, was also evaluated by means of ex-vivo tests in comparison to known compounds (example 9).

In particular, N-[3-mercaptop-2-(3,4-methylenedioxyphenyl)methyl-propionyl]-S-phenylalanine and N-[3-mercaptop-2-(3,4-methylenedioxyphenyl)methyl-propionyl]-S-tyrosine, described as enkephalinase and ACE-inhibitors in the aforementioned European patent application No. 0419327 and hereinafter referred to as compounds R-1 and R-2 respectively, as well as N-(3-mercaptop-2-methylpropanoyl)-L-tyrosine and N-(3-mercaptop-2-methylpropanoyl)-L-triptophan, described as ACE-inhibitors in U.S. 4,199,512 and as enkephalinase inhibitors in U.S. 4,401,677 and hereinafter referred to as compounds R-3 and R-4 respectively, were used as comparison compounds.

20 The ex-vivo ACE/NEP-inhibitory activity, in particular, was determined by evaluating the enzymatic activity in tissue homogenates (lung and kidney for ACE and NEP activity, respectively) from spontaneously hypertensive rats (SHR) treated with the tested compounds by intravenous or oral route.

It is worth noting that the activity shown by the compounds of formula I in the ex vivo tests 25 confirms the mixed activity (dual activity) shown in the in vitro tests, also after oral administration.

Said activity, moreover, resulted to be significantly higher than that of the comparison compounds.

For a practical use in therapy, the compounds of formula I can be formulated in solid or liquid 30 pharmaceutical compositions, suitable to oral or parenteral administration.

Therefore, the pharmaceutical compositions containing a therapeutically effective amount of a

- 9 -

compound of formula I in admixture with a carrier for pharmaceutical use are a further object of the present invention.

Specific examples of pharmaceutical compositions according to the present invention are tablets, coated tablets, capsules, granulates, solutions and suspensions suitable to oral administration, solutions and suspensions suitable to parenteral administration.

The pharmaceutical compositions object of the present invention are prepared according to conventional techniques.

The daily dose of the compound of formula I or of the corresponding pro-drug will depend on several factors such as the seriousness of the disease, the individual response of the patient or the kind of formulation but it is usually comprised between 0.1 mg and 10 mg per kg of body weight divided into a single dose or into more daily doses.

With the aim of illustrating the present invention the following examples are now given.

Unless otherwise specified, the flash chromatographies were carried out by using flash chromatography silica gel from Baker company (code 7024-00).

Example 1

Preparation of N-tert-butoxycarbonyl-4-(5-pyrimidinyl)-L-phenylalanine ethyl ester

A mixture of 5-pyrimidinylboronic acid (850 mg; 2 mmoles), N-tert-butoxycarbonyl-4-trifluoromethylsulphonyl-L-phenylalanine ethyl ester (450 mg; 2.2 mmoles), a solution of sodium carbonate (530 mg) in water (2.59 ml) and a mixture of toluene:ethanol=10:4.5 (20 ml) was degassed with nitrogen for 30 minutes.

Subsequently, palladium(0)tetrakis(triphenylphosphine) (120 mg; 0.06 mmoles) was therein added and the reaction mixture was heated at 90°C and kept under stirring for 3 hours.

The mixture was then kept at room temperature and N-tert-butoxycarbonyl-4-trifluoromethylsulphonyl-L-phenylalanine ethyl ester (112 mg) and palladium(0)tetrakis(triphenylphosphine) (30 mg) were added again.

The mixture was further heated at the temperature of 90°C and kept under stirring for other 18 hours.

After cooling the reaction mixture at room temperature, ethyl acetate (100 ml) and water (40 ml) were added.

The phases were separated and the organic phase was dried on sodium sulphate and evapo-

- 10 -

5 rated under vacuum. The obtained residue was purified by flash chromatography (silica gel, eluent hexane:ethyl acetate=7:3, pressure of nitrogen 0.1 atm) thus affording N-tert-butoxy-carbonyl-4-(5-pyrimidinyl)-L-phenylalanine ethyl ester (130 mg; 14% yield) as a colourless oil.

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 1.24 (t, 3H, CH₂-CH₃); 1.40 [s, 9H, C(CH₃)₃]; 3.01-3.25 (m, 2H, CH₂-CH); 4.19 (q, 2H, CH₂-CH₃); 4.52-4.65 (m, 1H, CH-COO); 5.06 (d, 1H, NH); 7.25-7.52 (m, 4H, phenylene); 8.91 (s, 2H, N-CH-C-CH-N); 9.19 (s, 1H, N-CH-N).

10 Example 2

Preparation of N-tert-butoxycarbonyl-4-(2-thiazolyl)-L-phenylalanine methyl ester

N-tert-butoxycarbonyl-4-(trifluoromethylsulphonyl)-L-phenylalanine methyl ester (8 g; 32.3 mmoles) and palladium-bis(triphenylphosphine) chloride (2.3 g) were added to a solution of 2-trimethylstannyl-thiazole (13.8 g; 32.3 mmoles) in a mixture of tetrahydrofuran: toluene=10:1 (50 ml), previously degassed with nitrogen.

The mixture was refluxed for 24 hours and, subsequently, 2-trimethylstannyly-thiazole (2 g) was added again.

After 6 hours at reflux N-tert-butoxycarbonyl-4-(trifluoromethylsulphonyl)-L-phenylalanine methyl ester (2 g) and palladium-bis(triphenylphosphine) chloride (700 mg) were added.

20 The resultant reaction mixture was kept under stirring at 70°C for 16 hours and, subsequently, cooled at room temperature.

Water (200 ml) was then added to the mixture which was extracted with methylene chloride (4x200 ml).

The collected organic phases were dried on sodium sulphate and evaporated under vacuum.

25 The obtained residue was purified by flash chromatography (silica gel, eluent methylene chloride:ethyl acetate=9:1, pressure of nitrogen=0.1 atm) thus affording N-tert-butoxycarbonyl-4-(2-thiazolyl)-L-phenylalanine methyl ester (2.3 g; 20% yield).

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 1.40 [s, 9H, C(CH₃)₃]; 3.00-3.21 (m, 2H, CH₂); 3.70 (s, 3H, COOCH₃); 4.42-4.65 (m, 1H, CH-COO); 5.02 (bd, 1H, NH); 7.30 (d, 1H, S-CH-CH-N); 7.81 (d, 1H, S-CH-CH-N), 7.15-7.90 (m, 4H, phenylene).

Example 3

- 11 -

Preparation of N-tert-butoxycarbonyl-4-(3-pyridyl)-L-phenylalanine methyl ester

3-Bromopyridine (1.67 g; 10 mmoles) and palladium(0)tetrakis(triphenylphosphine) (370 mg; 0.219 mmoles) were added to a solution of N-tert-butoxycarbonyl-4-(tributylstannyl)-L-5 phenylalanine methyl ester (4 g; 7.03 mmoles), prepared as described by D.S. Wilbur et al. in Bioconjugate Chem., 1973, 4, 574-580, in anhydrous dimethylformamide (30 ml), previously degassed with nitrogen.

The reaction mixture was kept under stirring for 10 minutes at room temperature and, subsequently, heated at 105°C for 6 hours.

10 Palladium(0)tetrakis(triphenylphosphine) (0.0035 mmoles) was again added and the mixture was kept under stirring at 105°C for 8 hours and then cooled at room temperature. Water (100 ml) was therein added and the reaction mixture was extracted with hexane (3x150 ml).

15 The collected organic phases were washed with a saturated aqueous solution of potassium fluoride, dried on sodium sulphate and evaporated under vacuum.

The obtained residue was collected with ethyl acetate and filtered.

The resultant solution was evaporated under vacuum and the residue was purified by flash chromatography (silica gel, eluent hexane:ethyl acetate=8:2, pressure of nitrogen 0.1 atm) affording N-tert-butoxycarbonyl-4-(3-pyridyl)-L-phenylalanine methyl ester (1.5 g; 60% yield) 20 as a colourless oil.

Mass (C.I.): $(M+H)^+ = 357$

1H -NMR (200 MHz, $CDCl_3$): δ (ppm): 1.40 [s, 9H, $C(CH_3)_3$]; 3.00-3.20 (m, 2H, CH_2); 3.71 (s, 3H, $COOCH_3$); 4.55 (m, 1H, $CH-COO$); 5.05 (bd, 1H, NH); 7.19-7.51 (m, 4H, phenylene); 7.30-8.82 (bm, 4H, pyridyl).

25 By working in an analogous way the following compounds were prepared:

N-tert-butoxycarbonyl-4-(2-pyridyl)-L-phenylalanine methyl ester

Mass (C.I.): $(M+H)^+ = 357$

1H -NMR (200 MHz, $CDCl_3$): δ (ppm): 1.40 [s, 9H, $C(CH_3)_3$]; 3.03-3.21 (m, 2H, CH_2-CH); 3.70 (s, 3H, $COOCH_3$); 4.54-4.65 (m, 1H, $CH-COO$); 4.98 (d, 1H, CONH); 7.16-7.21 (m, 1H, $N-C-CH-CH$); 7.65-7.77 (m, 2H, $N-CH-CH-CH$); 7.19-7.93 (m, 4H, phenylene); 8.63-8.68 (m, 1H, $N-CH$);

- 12 -

N-tert-butoxycarbonyl-4-(2-pyrazinyl)-L-phenylalanine methyl ester

5 $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ (ppm): 1.40 [s, 9H, $\text{C}(\text{CH}_3)_3$]; 3.02 (m, 2H, CH_2); 3.70 (s, 3H, COOCH_3); 4.53-4.70 (m, 1H, CH-COO); 5.03 (bd, 1H, NH); 7.21-7.98 (m, 4H, phenylene); 8.49 and 8.62 [2(bs, 2H, N-CH-CH-N)]; 9.00 (s, 1H, CH-N-CH-CH);

N-tert-butoxycarbonyl-4-(2-thienyl)-L-phenylalanine methyl ester

10 $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ (ppm): 1.41 [m, 9H, $\text{C}(\text{CH}_3)_3$]; 2.98-3.18 (m, 2H, CH_2); 3.71 (s, 3H, COOCH_3); 4.53-4.64 (m, 1H, CH-COO); 4.98 (bd, 1H, NH); 7.02-7.28 (m, 3H, thienyl); 7.10-7.54 (m, 4H, phenylene).

10 Example 4

Preparation of 4-(3-pyridyl)-L-phenylalanine methyl ester dihydrochloride

Thionyl chloride (0.85 ml; 4.78 mmoles) was added dropwise to a solution of N-tert-butoxycarbonyl-4-(3-pyridyl)-L-phenylalanine methyl ester (1.4 g; 3.93 mmoles) in methanol (30 ml), prepared as described in example 3, keeping the temperature at 0°C.

15 At the end of the addition, the reaction mixture was brought at room temperature and kept under stirring for 8 hours.

The solvent was then evaporated under vacuum affording 4-(3-pyridyl)-L-phenylalanine methyl ester dihydrochloride (820 mg; 71% yield) used as such in the following reactions.

Mass (C.I.): $(\text{M}+\text{H})^+ = 257$ (free base)

20 $^1\text{H-NMR}$ (200 MHz, D_2O): δ (ppm): 3.11-3.32 (m, 2H, CH_2); 3.67 (s, 3H, CH_3); 4.31-4.37 (m, 1H, CH); 7.30-7.63 (m, 4H, phenylene); 7.97 (dd, 1H, CH-N-CH-CH-CH); 8.59 (d, 1H, CH-N-CH-CH-CH); 8.65-8.71 (m, 1H, CH-N-CH-CH); 8.89 (d, 1H, CH-N-CH-CH-CH).

By working in an analogous way the following compounds were prepared:

4-(2-pyridyl)-L-phenylalanine methyl ester dihydrochloride

25 Mass (C.I.): $(\text{M}+\text{H})^+ = 257$ (free base)

$^1\text{H-NMR}$ (200 MHz, D_2O): δ (ppm): 3.12-3.33 (m, 2H, CH_2); 3.64 (s, 3H, CH_3); 4.30-4.37 (m, 1H, CH); 7.36-7.73 (m, 4H, phenylene); 7.78-8.58 (m, 4H, pyridyl);

4-(5-pyrimidinyl)-L-phenylalanine ethyl ester dihydrochloride

30 $^1\text{H-NMR}$ (200 MHz, DMSO-d_6): δ (ppm): 1.11 (t, 3H, $\text{CH}_2\text{-CH}_3$); 3.10-3.35 (m, 2H, $\text{CH}_2\text{-CH}$); 4.04-4.20 (m, 2H, $\text{CH}_2\text{-CH}_3$); 4.22-4.35 (m, 1H, CH); 7.40-7.84 (m, 4H, phenylene); 9.15 (s, 2H, N-CH-C-CH-N); 9.19 (s, 1H, N-CH-N);

- 13 -

4-(2-pyrazinyl)-L-phenylalanine methyl ester dihydrochloride

Mass (C.I.): $(M+H)^+$ = 258 (free base)

5 $^1\text{H-NMR}$ (200 MHz, DCl 1N): δ (ppm): 3.45-3.67 (m, 2H, CH_2); 3.98 (s, 3H, CH_3); 4.65-4.72 (m, 1H, CH); 7.68-8.26 (m, 4H, phenylene); 9.02 (d, 1H, CH-N-CH-CH); 9.44 (dd, 1H, CH-N-CH-CH); 9.54 (d, 1H, CH-N-CH-CH);

4-(2-thienyl)-L-phenylalanine methyl ester hydrochloride

Mass (C.I.): $(M+H)^+$ = 262 (free base)

10 $^1\text{H-NMR}$ (200 MHz, D_2O): δ (ppm): 2.98-3.19 (m, 2H, CH_2); 3.65 (s, 3H, CH_3); 4.21-4.28 (m, 1H, CH); 6.96-7.28 (m, 3H, thienyl); 7.08-7.52 (m, 4H, phenylene);

4-(2-thiazolyl)-L-phenylalanine methyl ester dihydrochloride

15 $^1\text{H-NMR}$ (200 MHz, D_2O): δ (ppm): 3.10-3.32 (m, 2H, $\text{CH}_2\text{-CH}$); 3.68 (s, 3H, CH_3); 4.30-4.38 (m, 1H, CH); 7.30-7.80 (m, 4H, phenylene); 7.70-7.91 (m, 2H, thiazolyl).

Example 5

15 Preparation of 2-isobutyl-3-phenylcarbonylthio-propionic acid

A mixture of 2-isobutyl-acrylic acid (6.34 g; 49 mmoles) and thiobenzoic acid (5.96 ml; 51 mmoles) was heated at 100°C under stirring for 2 hours.

The reaction mixture was then treated with petroleum ether 40-60°C (100 ml) and cooled at -70°C in a dry ice/acetone bath.

20 By filtration and washing with petroleum ether at -70°C a residue was collected which, dried at reduced pressure, furnished 2-isobutyl-3-phenylcarbonylthio-propionic acid (11.12 g; 85% yield) as a white solid.

$^1\text{H-NMR}$ (200 MHz, CDCl_3): δ (ppm): 0.90-1.00 (m, 6H); 1.40-1.90 (m, 3H); 2.70-2.90 (m, 1H); 3.10-3.40 (m, 2H); 7.35-7.62 (m, 3H); 7.90-8.00 (d, 2H).

25 By working in an analogous way the following compounds were prepared:

2-(3-methoxyphenyl)methyl-3-phenylcarbonylthio-propionic acid

$^1\text{H-NMR}$ (200 MHz, CDCl_3): δ (ppm): 2.32 (s, 3H); 2.80-3.15 (m, 5H); 3.77 (s, 3H); 6.70-6.80 (m, 3H); 7.14-7.25 (m, 1H).

3-acetylthio-2-(2-fluorophenyl)methyl-propionic acid

30 $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ (ppm): 2.31 (s, 3H); 2.90-3.20 (m, 5H); 6.95-7.30 (m, 4H).

3-phenylcarbonylthio-2-(2-thienyl)methyl-propionic acid benzylamine salt

- 14 -

¹H-NMR (200 MHz, DMSO-d₆): δ (ppm): 2.45-3.25 (m, 5H, S-CH₂-CH-CH₂); 3.90 (s, 2H, CH₂-phenyl); 6.85-7.91 (m, 13H, aryl).

Example 6

5 Preparation of N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester (compound 1)

A solution of hydroxybenzotriazole (0.54 g; 4 mmoles) in tetrahydrofuran (30 ml) and, subsequently, a solution of dicyclohexylcarbodiimide (0.825 g; 4 mmoles) in methylene chloride (15 ml) were added, at 0°C under stirring, to a mixture of (2S)-3-phenylcarbonylthio-2-phenylmethylpropionic acid (1.2 g; 4 mmoles), 4-(2-thiazolyl)-L-phenylalanine methyl ester dihydrochloride (1.34 g; 4 mmoles), prepared as described in example 4, triethylamine (1.11 ml; 8 mmoles) in tetrahydrofuran (20 ml) and methylene chloride (30 ml).

The reaction mixture was kept under stirring for 20 hours, then dicyclohexyl urea was filtered off and the solvent was evaporated at reduced pressure.

15 The residue was collected with ethyl acetate and the solution was washed with an aqueous solution of sodium chloride at 20%, sodium bicarbonate at 5% and sodium chloride at 20% again.

After separation of the phases and evaporation of the organic phase, the resultant white solid was purified by flash chromatography (silica gel, eluent ethyl acetate:hexane=40:60, pressure 20 of nitrogen 0.1 atm) thus affording N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester (1.5 g).

m.p. 98-100°C

Mass (C.I.): (M+H)⁺ = 545

1¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.63-3.35 (m, 7H, CH₂-CH-CH₂, CH₂-C₆H₄-thiazolyl); 3.68 (s, 3H, COOCH₃); 4.75-4.85 (m, 1H, CH-COO); 5.78 (d, 1H, NH); 7.10-8.00 (m, 16H, aryl).

By working in an analogous way, starting from compounds known or prepared as described in examples 4 and 5, the following compounds were obtained:

30 N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(2-furyl)-L-phenylalanine methyl ester (compound 2)

m.p. 132-134°C

- 15 -

Mass (C.I.) (M+H)⁺= 528

10 ¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.60-3.35 (m, 7H, CH₂-CH-CH₂, CH₂-C₆H₄-furyl); 3.58 (s, 3H, COOCH₃); 4.71-4.81 (m, 1H, CH-COO); 5.73 (d, 1H, NH); 6.40-8.00 (m, 17H, aryl);

15 N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(5-pyrimidinyl)-L-phenylalanine ethyl ester (compound 3)

m.p. 117-119°C

Mass (C.I.) (M+H)⁺= 554

10 ¹H-NMR (200 MHz, CDCl₃): δ (ppm): 1.18 (t, 3H, CH₃-CH₂); 2.65-3.35 (m, 7H, CH₂-CH-CH₂, CH₂-C₆H₄-pyrimidinyl); 3.95-4.20 (m, 2H, COOCH₂); 4.70-4.80 (m, 1H, CH-COO); 5.78 (d, 1H, NH); 7.05-8.00 (m, 14H, phenyl, phenylene); 8.68 (s, 2H, CH-N-CH-N-CH); 9.11 (s, 1H, N-CH-N);

15 N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(2-pyrazinyl)-L-phenylalanine methyl ester (compound 4)

m.p. 145-147°C

Mass (C.I.) (M+H)⁺= 540

10 ¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.65-3.35 (m, 7H, CH₂-CH-CH₂, CH₂-C₆H₄-pyrazinyl); 3.61 (s, 3H, COOCH₃); 4.75-4.85 (m, 1H, CH-COO); 5.78 (d, 1H, NH); 7.10-8.00 (m, 14H, phenyl, phenylene); 8.48-8.75 (m, 3H, CH-N-CH-CH-N);

15 N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(3-pyridyl)-L-phenylalanine methyl ester (compound 5)

m.p. 132-134°C

Mass (C.I.) (M+H)⁺= 539

20 ¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.66-2.79 (m, 1H, CH₂-CH-CH₂); 2.88-3.35 (m, 6H, CH₂-CH-CH₂, CH₂-C₆H₄-pyridyl); 3.61 (s, 3H, COOCH₃); 4.75-4.85 (m, 1H, CH-COO); 5.77 (d, 1H, NH); 7.07-7.99 (m, 16H, CH-CH-CH-N, phenyl, phenylene); 8.51-8.64 (m, 2H, CH-N-CH);

25 N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(2-pyridyl)-L-phenylalanine methyl ester (compound 6)

m.p. 123-125°C

- 16 -

Mass (C.I.) (M+H)⁺ = 539

5 ¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.63-2.77 (m, 1H, CH₂-CH-CH₂); 2.85-3.35 (m, 6H, CH₂-CH-CH₂, CH₂-C₆H₄-pyridyl); 3.56 (s, 3H, COOCH₃); 4.75-4.85 (m, 1H, CH-COO); 5.75 (d, 1H, NH); 7.09-7.99 (m, 16H, CH-CH-CH-N, phenyl, phenylene); 8.61-8.65 (m, 1H, N-CH-CH);

N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(2-thienyl)-L-phenylalanine methyl ester (compound 7)

Mass (C.I.) (M+H)⁺ = 544

10 ¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.64-3.36 (m, 7H, CH₂-CH-CH₂, CONH-CH-CH₂); 3.58 (s, 3H, COOCH₃); 4.74-4.83 (m, 1H, CH-COO); 5.74 (d, 1H, NH); 6.97-7.99 (m, 17H, aryl);

N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(3-thienyl)-L-phenylalanine methyl ester (compound 8)

15 Mass (C.I.) (M+H)⁺ = 544

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.63-3.35 (m, 7H, CH₂-CH-CH₂, NH-CH-CH₂); 3.58 (s, 3H, COOCH₃); 4.73-4.85 (m, 1H, CH-COO); 5.70-5.76 (bd, 1H, NH); 7.00-7.62 (m, 15H, phenyl, phenylene, CH-CH-S); 7.93-8.00 (m, 2H, CH-S-CH);

20 N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(3-furyl)-L-phenylalanine methyl ester (compound 9)

m.p. 115-117°C

Mass (C.I.) (M+H)⁺ = 528

15 ¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.62-3.36 (m, 7H, CH₂-CH-CH₂, NH-CH-CH₂); 3.58 (s, 3H, COOCH₃); 4.71-4.82 (m, 1H, CH-COO); 5.72 (bd, 1H, NH); 6.50-8.00 (m, 17H, aryl);

N-[(3-phenylcarbonylthio-2-(3-pyridylmethyl)propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester - stereoisomer A (compound 10)

Mass (C.I.) (M+H)⁺ = 546

TLC (ethyl acetate:petroleum ether=95:5), R_f = 0.33

30 ¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.60-3.38 (m, 7H, CH₂-CH-CH₂, NH-CH-CH₂); 3.60 (s, 3H, COOCH₃); 4.79-4.90 (m, 1H, CH-COO); 6.21 (bd, 1H, NH); 7.29-7.81 (m, 2H,

- 17 -

thiazolyl); 6.75-8.48 (m, 13H, phenyl, phenylene, pyridyl);

N-[3-phenylcarbonylthio-2-(3-pyridylmethyl)propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester - stereoisomer B (compound 11)

5 Mass (C.I.) (M+H)⁺ = 546

TLC (ethyl acetate:petroleum ether=95:5), R_f = 0.24

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.61-3.25 (m, 7H, CH₂-CH-CH₂, NH-CH-CH₂); 3.60 (s, 3H, COOCH₃); 4.80-4.91 (m, 1H, CH-COO); 6.09 (bd, 1H, NH); 7.27-7.80 (m, 2H, thiazolyl); 7.10-8.40 (m, 13H, phenyl, phenylene, pyridyl);

10 N-[2-isobutyl-3-phenylcarbonylthio-propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester (compound 12)

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 0.80-0.95 (m, 6H); 1.30-1.80 (m, 3H); 2.40-2.60 (m, 1H); 3.00-3.30 (m, 4H); 3.70 (d, 3H); 4.90-5.05 (m, 1H); 6.00-6.15 (bt, 1H); 7.10-8.00 (m, 11H);

15 N-[3-acetylthio-2-(3-methoxyphenyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester (compound 13)

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.30 (d, 3H); 2.45-3.20 (m, 7H); 3.63 (d, 3H); 3.75 (d, 3H); 4.70-4.93 (m, 1H); 5.70-5.90 (dd, 1H); 6.60-6.85 (m, 4H); 7.17-7.32 (m, 3H); 7.68-7.90 (m, 3H);

20 N-[3-acetylthio-2-(3-fluorophenyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester (compound 14)

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.29 (s, 3H); 2.55-3.20 (m, 7H); 3.65 (2s, 3H); 4.70-4.90 (m, 1H); 5.80-6.00 (2d, 1H); 6.70-7.32 (m, 3H);

N-[3-phenylcarbonylthio-2-(2-thienyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine

25 methyl ester (compound 15)

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 2.68-3.37 (m, 7H); 3.60-3.61 (2s, 3H, COOCH₃); 4.31-4.45 (m, 1H, CH-COOCH₃); 6.01-6.10 (2d, 1H, NH); 6.80-8.00 (m, 14H);

Example 7

Preparation of N-[(2S)-3-mercaptop-2-phenylmethylpropionyl]-4-(2-thiazolyl)-L-phenylalanine

30 (compound 16)

N-[(2S)-3-phenylcarbonylthio-2-phenylmethylpropionyl]-4-(2-thiazolyl)-L-phenylalanine

- 18 -

methyl ester (1.4 g, 2.57 mmoles), prepared as described in example 6, was suspended in ethanol (30 ml), degassed by nitrogen bubbling to eliminate the oxygen.

An aqueous degassed solution of sodium hydroxide 1N (7.7 ml) and, at the end of the addition, further degassed ethanol (20 ml) were added dropwise at 5°C to the suspension.

The reaction mixture was kept under stirring for 4 hours at room temperature, then cooled at 0°C and acidified with hydrochloric acid 5% (10 ml).

The reaction mixture was evaporated to dryness and the residue was collected with acetonitrile and water and, subsequently, was filtered thus affording N-[(2S)-3-mercaptop-2-phenylmethyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine (1 g).

m.p. 180-182°C

Mass (C.I.) (M+H)⁺ = 427

¹H-NMR (200 MHz, DMSO-d₆): δ (ppm): 1.80-1.88 (m, 1H, SH); 2.22-2.84 (m, 5H, CH₂-CH-CH₂); 2.86-3.18 (m, 2H, CH₂-CH-COO); 4.46-4.57 (m, 1H, CH-COO); 7.10-7.25 (m, 5H, phenyl); 7.32-7.84 (m, 4H, phenylene); 7.74 (d, 1H, N-CH=CH-S); 7.89 (d, 1H, N-CH=CH-S); 8.35 (d, 1H, NH); 12.76 (s, 1H, COOH);

By working in an analogous way the following compounds were prepared:

N-[(2R)-3-mercaptop-2-phenylmethylpropionyl]-4-(2-thiazolyl)-L-phenylalanine (compound 17)

¹H-NMR (200 MHz, DMSO-d₆): δ (ppm): 2.15-2.23 (m, 1H, SH); 2.31-2.74 (m, 5H, CH₂-CH-CH₂); 2.78-3.07 (m, 2H, CH₂-CH-COO); 4.42-4.53 (m, 1H, CH-COO); 7.02-7.80 (m, 9H, phenyl and phenylene); 7.75 (d, 1H, N-CH=CH-S); 7.90 (d, 1H, N-CH=CH-S); 8.36 (d, 1H, NH);

N-[(2S)-3-mercaptop-2-phenylmethylpropionyl]-4-(2-furyl)-L-phenylalanine (compound 18)

m.p. 153-155°C

25 Mass (C.I.) (M+H)⁺ = 410

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 1.40 (t, 1H, SH); 2.45-3.25 (m, 7H, CH₂-CH-CH₂, CH₂-CH-COO); 4.80-4.90 (m, 1H, CH-COO); 5.86 (d, 1H, NH); 6.42-7.42 (m, 3H, furyl); 7.07-7.57 (m, 9H, phenyl, phenylene);

N-[(2S)-3-mercaptop-2-phenylmethylpropionyl]-4-(5-pyrimidinyl)-L-phenylalanine (compound

30 19)

m.p. 193-195°C

- 19 -

Mass (C.I.) (M+H)⁺ = 422

1^H-NMR (200 MHz, DMSO-d₆): δ (ppm): 1.81 (bm, 1H, SH); 2.21-3.20 (m, 7H, CH₂-CH-CH₂, CH₂-C₆H₄-pyrimidinyl); 4.46-4.57 (m, 1H, CH-COO); 7.06-7.29 (m, 5H, phenyl); 5 7.36-7.72 (m, 4H, phenylene); 8.33 (d, 1H, NHCO); 9.08 (s, 2H, N-CH-C-CH-N); 9.15 (s, 1H, N-CH-N);

N-[(2S)-3-mercaptop-2-phenylmethylpropionyl]-4-(2-pyrazinyl)-L-phenylalanine (compound 20)

m.p. 176-178°C

10 Mass (C.I.) (M+H)⁺ = 422

1^H-NMR (200 MHz, DMSO-d₆): δ (ppm): 1.84 (bt, 1H, SH); 2.21-3.21 (m, 7H, CH₂-CH-CH₂, CH₂-CH-COO); 4.48-4.59 (m, 1H, CH-COO); 7.10-7.26 (m, 5H, phenyl); 7.37-8.05 (m, 4H, phenylene); 8.37 (d, 1H, NHCO); 8.58 (d, 1H, CH-N-CH-CH-N); 8.68-8.70 (m, 1H, CH-N-CH-CH-N); 9.21 (d, 1H, C-CH-N); 12.78 (b, 1H, COOH);

15 N-[(2S)-3-mercaptop-2-phenylmethylpropionyl]-4-(3-pyridyl)-L-phenylalanine (compound 21)

m.p. 146-148°C

Mass (C.I.) (M+H)⁺ = 421

1^H-NMR (200 MHz, DMSO-d₆): δ (ppm): 1.69-1.89 (b, 1H, SH); 2.22-3.18 (m, 7H, CH₂-CH-CH₂, CH₂-phenylene); 4.45-4.56 (m, 1H, CH-COO); 7.09-7.26 (m, 5H, phenyl); 7.42-20 7.48 (m, 1H, CH-N-CH-CH-CH); 7.62-7.33 (m, 4H, phenylene); 7.98-8.04 (m, 1H, CH-N-CH-CH-CH); 8.30 (d, 1H, CONH); 8.53 (dd, 1H, CH-N-CH-CH-CH); 8.83 (d, 1H, CH-N-CH-CH-CH);

N-[(2S)-3-mercaptop-2-phenylmethylpropionyl]-4-(2-pyridyl)-L-phenylalanine (compound 22)

m.p. 157-159°C

25 Mass (C.I.) (M+H)⁺ = 421

1^H-NMR (200 MHz, DMSO-d₆): δ (ppm): 1.87 (b, 1H, SH); 2.23-3.19 (m, 7H, S-CH₂-CH-CH₂, CONH-CH-CH₂); 4.44-4.45 (m, 1H, CH-COO); 7.09-7.93 (m, 8H, N-CH-CH-CH-CH, phenyl); 7.30-7.99 (m, 4H, phenylene); 8.29 (d, 1H, CONH); 8.61-8.65 (m, 1H, C-N-CH);

30 N-[(2S)-3-mercaptop-2-phenylmethylpropionyl]-4-(2-thienyl)-L-phenylalanine (compound 23)

m.p. 152-154°C

- 20 -

¹H-NMR (200 MHz, CDCl₃): δ (ppm): 1.34-1.43 (m, 1H, SH); 2.44-3.26 (m, 7H, S-CH₂-CH-CH₂, CONH-CH-CH₂); 4.80-4.89 (m, 1H, NH-CH-COO); 5.81 (d, 1H, NH); 7.02-7.52 (m, 12H, aryl);

5 N-[(2S)-3-mercaptop-2-phenylmethylpropionyl]-4-(3-thienyl)-L-phenylalanine (compound 24)
 m.p. 169-171°C
 Mass (C.I.) (M+H)⁺= 426
 TLC (ethyl acetate:hexane:acetic acid=50:50:5), R_f = 0.44
¹H-NMR (200 MHz, CDCl₃): δ (ppm): 1.84 (bs, 1H, SH); 2.23-3.13 (m, 7H, S-CH₂-CH-CH₂, NH-CH-CH₂); 4.42-4.53 (m, 1H, NH-CH-COO); 7.12-7.80 (m, 12H, aryl); 8.30 (d, 1H, JHH=8.2 Hz, NH);

10 N-[(2S)-3-mercaptop-2-phenylmethylpropionyl]-4-(3-furyl)-L-phenylalanine (compound 25)
 m.p. 140-142°C
 Mass (C.I.) (M+H)⁺= 410
 TLC (ethyl acetate:hexane:acetic acid=50:50:5), R_f = 0.42
¹H-NMR (200 MHz, CDCl₃): δ (ppm): 1.79-1.90 (m, 1H, SH); 2.22-3.11 (m, 7H, S-CH₂-CH-CH₂, NH-CH-CH₂); 4.41-4.53 (m, 1H, NH-CH-COO); 7.11-7.50 (m, 9H, phenyl, phenylene); 6.91-8.12 (m, 3H, furyl); 8.30 (d, 1H, JHH=8.2 Hz, NH);
N-[3-mercaptop-2-(3-pyridylmethyl)propionyl]-4-(2-thiazolyl)-L-phenylalanine - stereoisomer

15 A (compound 26)
 m.p. 193-196°C
 Mass (C.I.) (M+H)⁺= 428
 TLC (methylene chloride:methanol:acetic acid=85:15:1.5), R_f = 0.53
¹H-NMR (200 MHz, DMSO-d₆): δ (ppm): 2.37-3.05 (m, 7H, S-CH₂-CH-CH₂, NH-CH-CH₂); 4.36-4.47 (m, 1H, NH-CH-COO); 7.76-7.90 (m, 2H, thiazolyl); 7.10-8.33 (m, 9H, NH, pyridyl, phenylene);
N-[3-mercaptop-2-(3-pyridylmethyl)propionyl]-4-(2-thiazolyl)-L-phenylalanine - stereoisomer

20 B (compound 27)
 Mass (C.I.) (M+H)⁺= 428
 TLC (methylene chloride:methanol:acetic acid=85:15:1.5), R_f = 0.47
¹H-NMR (200 MHz, DMSO-d₆): δ (ppm): 2.28-3.20 (m, 7H, S-CH₂-CH-CH₂, NH-CH-

- 21 -

CH_2); 4.20-4.35 (m, 1H, $\text{NH-CH}_2\text{-COO}$); 7.70-7.90 (m, 2H, thiazolyl); 7.17-8.40 (m, 9H, NH, pyridyl, phenylene);

N-(2-isobutyl-3-mercaptopropiyl)-4-(2-thiazolyl)-L-phenylalanine (compound 28)

5 $^1\text{H-NMR}$ (200 MHz, DMSO-d₆): δ (ppm): 0.50-1.44 (m, 9H); 1.68-2.25 (m, 4H); 2.79-3.22 (m, 2H); 4.50-4.63 (m, 1H); 7.34-7.85 (m, 4H); 7.73-7.90 (m, 2H); 8.27-8.39 (2d, 1H); Mass (C.I.) (M+H)⁺ = 393

N-[3-mercaptopro-2-(3-methoxyphenyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine (compound 29)

10 Mass (C.I.) (M+H)⁺ = 457
 $^1\text{H-NMR}$ (200 MHz, DMSO-d₆+D₂O): δ (ppm): 2.20-3.21 (m, 7H); 3.70 (d, 3H); 4.48 (m, 1H); 6.55-6.86 (m, 3H); 7.00-7.40 (m, 3H); 7.65-7.95 (m, 4H); 8.27-8.45 (bt, CONH);

N-[3-mercaptopro-2-(2-fluorophenyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine (compound 30)

15 Mass (C.I.) (M+H)⁺ = 445
 $^1\text{H-NMR}$ (200 MHz, DMSO-d₆): δ (ppm): 2.20-3.18 (m, 8H); 4.35-4.55 (m, 1H); 6.85-7.35 (m, 6H); 7.65-7.90 (m, 4H); 8.35 (d, 1H);

N-[3-mercaptopro-2-(2-thienyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine (compound 31)

20 $^1\text{H-NMR}$ (200 MHz, DMSO-d₆): δ (ppm): 1.82-3.19 (m, 8H, $\text{CH}_2\text{-CH}_2\text{-CH}_2$; NH-CH- CH_2); 4.44-4.59 (m, 1H, CH-COO); 6.62-7.91 (m, 9H, aryl); 8.42 (d, 1H, NH);

N-[3-mercaptopro-2-(2-furyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine (compound 32)

25 $^1\text{H-NMR}$ (200 MHz, DMSO-d₆): δ (ppm): 1.79-3.18 (m, 8H, S- $\text{CH}_2\text{-CH}_2\text{-CH}_2$; NH-CH- CH_2); 4.43-4.58 (m, 4H, CH-NH); 5.79-7.47 (m, 3H, furyl); 7.30-7.85 (m, 4H, phenylene); 7.73-7.91 (m, 2H, thiazolyl); 8.40-8.46 (2d, 1H, NH);

30 N-[3-mercaptopro-2-(3-methyl-5-isoxazolyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine (compound 33)

$^1\text{H-NMR}$ (200 MHz, DMSO-d₆): δ (ppm): 2.00-2.12 (2S, 3H, CH_3 -isoxazolyl); 2.28-3.19 (m, 8H, S- $\text{CH}_2\text{-CH}_2\text{-CH}_2$; CH_2 -phenylene); 4.43-4.59 (m, 1H, CH-NH); 5.75-6.03 (2s, 1H, isoxazolyl); 7.29-7.86 (m, 4H, phenylene); 7.74-7.90 (m, 2H, thiazolyl); 8.46-8.53 (2d, 1H,

35 NH);

Example 8

- 22 -

In vitro evaluation of the pharmacologic activity

a) NEP-inhibitory activity

5 The NEP-inhibitory activity was evaluated in rat kidney cortex membranes prepared according to the procedure described by T. Maeda et al. in *Biochim. Biophys. Acta* 1983, 731(1), 115-120.

Kidneys were removed from male Sprague-Dawley rats weighing approximately 300 g and kept at 4°C.

10 Kidney cortex was carefully dissected, finely minced and suspended in a homogenization buffer (10 mM sodium phosphate pH 7.4 containing 1 mM MgCl₂, 30 mM NaCl, 0.02% NaN₃) 1:15 weight/volume.

15 The tissue was then cold homogenized for 30 seconds using an Ultra-Turrax homogenizer. Approximately 10 ml of homogenate were layered over 10 ml of sucrose (41% weight/volume) and centrifuged at 31200 rpm for 30 minutes at 4°C in a fixed angle rotor. The membranes were collected from the buffer/sucrose interface, washed twice with 50 mM TRIS/HCl buffer (pH 7.4) and resuspended into the same buffer for storage in small aliquots at -80°C until use.

20 The NEP-inhibitory activity was evaluated by using the method described by C. Llorens et al., in *Eur. J. Pharmacol.*, 69, (1981), 113-116, as herinafter reported.

25 Aliquots of the membrane suspension prepared as above described (concentration 5 µg/ml of proteins) were preincubated in the presence of an aminopeptidase inhibitor (Bestatin - 1 mM) for 10 minutes at 30°C.

[³H][Leu⁵]-enkephaline (15 nM) and buffer TRIS/HCl pH 7.4 (50 mM) were added in order to obtain a final volume of 100 µl.

30 Incubation (20 minutes at 30°C) was stopped by adding HCl 0.1M (100 µl).

The formation of the metabolite [³H]Tyr-Gly-Gly was quantified by chromatography on polystyrene columns (Porapak Q).

35 The percentage of inhibition of the metabolite formation in the membrane preparations treated with the compounds of formula I and with the comparative compounds with respect to the untreated membrane preparations was expressed as IC₅₀ (nM) value.

b) ACE-inhibitory activity

- 23 -

The ACE-inhibitory activity was evaluated according to the method reported in the literature by B. Holmquist et al., in *Analytical Biochemistry* 95, 540-548 (1979).

5 50 μ M of ACE (250 mU/ml purified by lung rabbit, EC 3.4.15.1 SIGMA) were preincubated with 50 μ l of the compound of formula I or of the reference compound or related vehicle in thermostated cuvettes at 37°C.

The reaction was started by adding furylacryloylphenylalanylglycylglycine 0.8 mM (FAPGG-SIGMA).

10 Contemporaneously, by using a Beckman DU-50 spectrophotometer provided with a program for calculating delta A/minutes and regression coefficients of the enzyme kinetics curves, the absorbance at 340 nm was recorded in continuo for 5 minutes.

The percentage of the enzyme inhibition in the preparations treated with the compounds of formula I or with the comparative compounds with respect to the untreated preparations was expressed as IC₅₀ (nM) value.

15 The IC₅₀ (nM) values related to the ACE-inhibitory activity and NEP-inhibitory activity of the compounds 16, 18-25, 27-33 and of the comparison compounds Thiorphan and Captopril are reported in the following table I.

- 24 -

Table 1

ACE-inhibitory and NEP-inhibitory activity, expressed as IC₅₀ (nM) value, of compounds 16, 18-25, 27-33 and of Thiorphan and Captopril.

Compound	ACE-inhibitory activity IC ₅₀ (nM)	NEP-inhibitory activity IC ₅₀ (nM)
16	3.2	1.8
18	1.8	1.8
19	1.9	1.8
20	1.5	2.5
21	1.7	2.6
22	1.8	2.0
23	1.6	0.6
24	2.5	1.3
25	2.4	1
27	9.1	17.3
28	5.8	1.8
29	4.6	9.0
30	10.7	11.2
31	8.6	1.2
32	8.6	4.0
33	7.9	4.5
Thiorphan	99	18
Captopril	4.6	not active

25

30

- 25 -

The data reported in table 1 show that the compounds of formula I, object of the present invention, are endowed with a significant mixed ACE/NEP inhibitory activity. Said activity is comparable to that of Captopril, to what it concerns the ACE inhibitory activity, and greater than that of Thiorphan, to what it concerns the NEP inhibitory activity.

Example 9

"Ex vivo" evaluation of the pharmacologic activity

a) NEP-inhibitory activity

10 The ex vivo NEP-inhibitory activity was evaluated according to the procedure reported in the literature by M. Orlowsky et al., in Biochemistry 1981, 20, 4942-4950.

The inhibitory activity of the compounds of formula I was evaluated in kidneys of spontaneously hypertensive rats (SHR), 5 minutes after i.v. injection (0.6 and 21 μ moles/kg) and 30 minutes, 60 minutes and 4 hours after oral administration (30 μ moles/kg) of the tested compounds.

15 After the removal of the kidneys from SHR, the renal tissue was homogenized and incubated for 15 minutes at 37°C in the presence of Glutaryl-Ala-Ala-Phe-2-naphthylamide (GAAP), as a substrate, and aminopeptidase M at pH 7.6.

The reaction was stopped by adding an aqueous solution at 10% of trichloroacetic acid.

The released 2-naphthylamine was determined by adding fast gamet dye (2 ml).

20 Enzyme reaction rates were determined by measuring the increase in the optical density at
524 nm (OD_{524}) with respect to a standard obtained with 2-naphthylamine complexed
with fast gamet.

The NEP-inhibitory activity of the tested compounds was expressed as percentage of NEP-inhibition in SHR kidneys.

25 b) ACE-inhibitory activity

The ex vivo ACE-inhibitory activity was evaluated by using a radiometric assay method, as reported in the literature by J. W. Ryan et al. in Biochem. J. (1977), 167, 501-504.

The inhibitory activity of the compounds of formula I was evaluated in lungs of spontaneously hypertensive rats (SHR), 5 minutes after i.v. injection (0.6 and 21 μ moles/kg) and 30 minutes, 60 minutes and 4 hours after oral administration (30 μ moles/kg) of the tested compounds.

- 26 -

After the removal of the lungs from SHR, the lung tissue was homogenized and incubated for 2 hours at 37°C in the presence of [³H]Hyp-Gly-Gly, as a substrate.

The reaction was stopped by adding hydrochloric acid.

5 The released radiolabelled hyppuric acid was extracted with ethyl acetate and counted by liquid scintillation spectrometry, according to conventional methods.

The ACE-inhibitory activity of the tested compounds was expressed as percentage of ACE-inhibition in SHR lungs.

10 As an example, the percentages of basal enzymatic activity obtained in the ex vivo tests after intravenous or oral administration of compound 16 and of comparison compounds R-1, R-2, R-3 and R-4 are reported in the following table 2.

Table 2

Percentages of ex vivo ACE-inhibition and NEP-inhibition of compound 16 and of compounds R-1, R-2, R-3 and R-4.

15	Compound	Treatment	ACE-inhibition (lungs)		NEP-inhibition (kidneys)	
			5 minutes	60 minutes	5 minutes	60 minutes
16	i.v. (0.6 µmoles/kg)		15%		34%	
16	i.v. (21 µmoles/kg)		72%		49%	
16	oral (30 µmoles/kg)			36%		39%
			30 minutes	4 hours	30 minutes	4 hours
16	oral (30 µmoles/kg)		60%	45%	55%	40%
R-1	oral (30 µmoles/kg)		25%	20%	5%	not active
R-2	oral (30 µmoles/kg)		30%	25%	30%	not active
R-3	oral (30 µmoles/kg)		25%	20%	10%	5%
R-4	oral (30 µmoles/kg)		25%	10%	not active	not active


20 The data reported in table 2 confirm that the compounds of formula I, object of the present invention, are endowed with a significant ACE/NEP-inhibitory activity after intravenous administration as well as after oral administration.

25 The ex-vivo ACE/NEP-inhibitory activity of the compounds of formula I, moreover, results to be significantly higher than that of the comparison compounds.

- 27 -

Claims

1) A compound of formula



wherein

10 R is a mercapto group or a R_4COS group convertible in the organism to mercapto group; R_1 is a straight or branched $\text{C}_2\text{-C}_4$ alkyl group or an aryl or arylalkyl group having from 1 to 6 carbon atoms in the alkyl moiety wherein the aryl is a phenyl or a 5 or 6 membered aromatic heterocycle with one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, optionally substituted with one or more substituents, the same or different, selected from the group consisting of halogen atoms, hydroxy groups, alkoxy, alkyl, alkylthio, alkylsulphonyl or alkoxy carbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety, $\text{C}_1\text{-C}_3$ alkyl groups containing one or more fluorine atoms, carboxy groups, nitro groups, amino or aminocarbonyl groups, acylamino groups, amino-sulphonyl groups, mono- or di-alkylamino or mono- or di-alkylaminocarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety;

15 R_2 is a hydrogen atom, a straight or branched $\text{C}_1\text{-C}_4$ alkyl or a benzyl group; R_3 is a phenyl group substituted by a 5 or 6 membered aromatic heterocycle with one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, being the phenyl and the heterocyclic groups optionally substituted with one or more substituents, the same or different, as indicated for R_1 ;

20 R_4 is a straight or branched $\text{C}_1\text{-C}_4$ alkyl group or a phenyl group; the carbon atoms marked with an asterisk are stereogenic centers; and pharmaceutically acceptable salts thereof.

25 2) A compound of formula I according to claim 1 wherein R_3 is a phenyl group substituted in position 4 with a heterocyclic group.

30 3) A compound of formula I according to claim 2 wherein R_1 represents an arylalkyl group optionally substituted with one or more substituents, the same or different, selected from the groups consisting of halogen atoms, hydroxy, alkyl or alkoxy groups.

- 28 -

4) A compound of formula I according to claim 3 wherein R_1 represents a phenylalkyl group optionally substituted with one or more substituents, the same or different, selected among halogen atoms, hydroxy, alkyl or alkoxy groups.

5) A compound of formula I according to claim 1 in the form of a salt with an alkali metal selected from the group consisting of sodium, lithium and potassium.


6) A process for the preparation of a compound of formula I according to claim 1 comprising the reaction between a compound of formula



wherein

R and R_1 have the above reported meanings;

15 and a phenylalanine derivative of formula



20 wherein

R_2 and R_3 have the above reported meanings.

7) A pharmaceutical composition containing a therapeutically effective amount of a compound of formula I according to claim 1 in admixture with a carrier for pharmaceutical use.

8) A pharmaceutical composition according to claim 6 for the treatment of cardiovascular diseases.

25

9) A method for the treatment of cardiovascular diseases comprising the administration of a therapeutically effective amount of a compound according to claim 1.

10) A compound selected from the group consisting of:

30 N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-thiazolyl)-L-phenylalanine methyl ester;

N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-pyridyl)-L-phenylalanine methyl ester;

N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(3-pyridyl)-L-phenylalanine benzyl ester;

- 29 -

N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-furyl)-L-phenylalanine methyl ester;
N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(5-pyrimidinyl)-L-phenylalanine ethyl ester;

5 N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-pyrazinyl)-L-phenylalanine methyl ester;
N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(2-thienyl)-L-phenylalanine methyl ester;
N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(3-thienyl)-L-phenylalanine methyl ester;

10 N-(3-phenylcarbonylthio-2-phenylmethylpropionyl)-4-(3-furyl)-L-phenylalanine methyl ester;
N-[3-phenylcarbonylthio-2-(3-pyridylmethyl)propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester;
N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-thiazolyl)-L-phenylalanine;

15 15 N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-pyridyl)-L-phenylalanine;
N-(3-mercaptop-2-phenylmethylpropionyl)-4-(3-pyridyl)-L-phenylalanine;
N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-furyl)-L-phenylalanine;
N-(3-mercaptop-2-phenylmethylpropionyl)-4-(5-pyrimidinyl)-L-phenylalanine;
N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-pyrazinyl)-L-phenylalanine;

20 20 N-(3-mercaptop-2-phenylmethylpropionyl)-4-(2-thienyl)-L-phenylalanine;
N-(3-mercaptop-2-phenylmethylpropionyl)-4-(3-thienyl)-L-phenylalanine;
N-(3-mercaptop-2-phenylmethylpropionyl)-4-(3-furyl)-L-phenylalanine;
N-[3-mercaptop-2-(3-pyridylmethyl)propionyl]-4-(2-thiazolyl)-L-phenylalanine;
N-[3-acetylthio-2-(3-methoxyphenyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine

25 25 methyl ester;
N-[3-acetylthio-2-(2-fluorophenyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester;
N-[3-phenylcarbonylthio-2-(2-thienyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester;

30 30 N-[2-(2-furyl)methyl-3-phenylcarbonylthio-propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester;

- 30 -

N-[2-(3-methyl-5-isoxazolyl)methyl-3-phenylcarbonylthio-propionyl]-4-(2-thiazolyl)-L-phenylalanine methyl ester;

N-[3-mercaptop-2-(3-methoxyphenyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine;

5 N-[3-mercaptop-2-(2-thienyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine;

N-[3-mercaptop-2-(3-methyl-5-isoxazolyl)methyl-propionyl]-4-(2-thiazolyl)-L-phenylalanine;

N-[2-(2-fluorophenyl)methyl-3-mercaptop-propionyl]-4-(2-thiazolyl)-L-phenylalanine;

N-[2-(2-furyl)methyl-3-mercaptop-propionyl]-4-(2-thiazolyl)-L-phenylalanine;

and the stereoisomers (2S) or (2R) thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/05663

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D277/30	A61K31/425	C07D213/55	C07D307/54	C07D239/26
C07D333/24	C07D241/12	C07D417/12		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J.MED.CHEM., vol. 37, 1994, pages 1070-1083, XP002029219 FOURNIÈ-ZALUSKI: "New dual inhibitors of neutral ..." see page 1073, tables 1 and 2 ---	1-10
Y	EP 0 539 848 A (INST NAT SANTE RECH MED ;RHONE POULENC RORER SA (FR)) 5 May 1993 see the whole document ---	1-10
Y	US 4 401 677 A (GREENBERG ROLAND ET AL) 30 August 1983 cited in the application see the whole document ---	1-10 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents such combination being obvious to a person skilled in the art
- *A* document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

10 April 1997

20.05.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Steendijk, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/05663

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 419 327 A (BIOPROJET SOC CIV) 27 March 1991 cited in the application see the whole document ---	1-10
A	BIOORG. MED. CHEM. LETT., vol. 5, no. 7, 1995, pages 735-738, XP002029220 BHAGWHAT ET AL.: "Alpha-Mercaptoacyl dipeptides that inhibit angiotensin ..." cited in the application see page 737, table 1 ---	1-10
P,X	BIOORG. MED. CHEM. LETT. (BMCL8,0960894X);96; VOL.6 (19); PP.2317-2322, HOECHST MARION ROUSSEL;CENTRE RECHERCHES ROUSSEL UCLAF; ROMAINVILLE; 93235; FR. (FR), XP002029221 DEPREZ P ET AL: "Thiol inhibitors of endothelin-converting enzyme" see page 2321, table 2 ---	1-10
P,Y	WO 96 22998 A (ZAMBON SPA ;PELLACINI FRANCO (IT); ROMAGNANO STEFANO (IT); NORCINI) 1 August 1996 see the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 96/05663

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0539848 A	05-05-93	FR 2682952 A AU 666141 B AU 2789592 A CA 2121801 A WO 9308162 A EP 0609310 A JP 7509441 T	30-04-93 01-02-96 21-05-93 29-04-93 29-04-93 10-08-94 19-10-95
US 4401677 A	30-08-83	US 4474795 A US 4474799 A	02-10-84 02-10-84
EP 0419327 A	27-03-91	FR 2652087 A AT 109131 T CA 2039706 A DE 69011024 D DE 69011024 T ES 2057477 T WO 9104246 A JP 4501868 T US 5599951 A	22-03-91 15-08-94 16-03-91 01-09-94 10-11-94 16-10-94 04-04-91 02-04-92 04-02-97
WO 9622998 A	01-08-96	IT MI950132 A AU 4620796 A	29-07-96 14-08-96